A multiplex real-time PCR (quantitative PCR [qPCR]) assay detecting herpes simplex virus (HSV) and varicella-zoster virus (VZV)DNAH erpes simplex viruses 1 and 2 (HSV-1 and -2, respectively) and varicella-zoster virus (VZV) are human double-stranded DNA viruses belonging to the Herpesviridae family. In immunocompetent hosts, benign vesicular eruption of the skin and mucosa occurs during either the primary infection or reactivation episodes (1). However, life-threatening manifestations, mainly related to virus neurovirulence, can be observed (2), HSV-1 and VZV being the first and second most common causes of viral encephalitis, respectively (3, 4). These viruses are associated with mortality and morbidity, especially when treatment with acyclovir is delayed (5). HSV-2 is more likely responsible for meningitis (1). HSV-2 and VZV are also implicated in neonatal infections (1,6,7).Due to similarities in the clinical presentations of the diseases caused by these 3 herpesviruses and other pathogens, virological testing is often needed. Accurate and specific diagnosis is of special importance in cases of severe infection or in infection occurring in immunosuppressed patients who can present atypical clinical pictures (8). In replacement of cell culture and immune detection of viral antigens, molecular assays are currently the main tool used for the virological diagnosis of infections related to HSV and VZV. This trend is due to the multiple advantages of nucleic acid testing (NAT), including the rapid availability of results, its adaptation to a wide diversity of clinical specimens, the capacity for automation, and, mostly, its high sensitivity and specificity. Several FDA-approved or CE-marked in vitro diagnostic (IVD) kits are available for detecting these viruses in various specimens (9-11). However, all of them propose separate detection for HSV and VZV DNA, and only a few multiplex assays including both agents have been published as laboratory-developed tests (LDTs) (10, 12).Although detection of viral DNA is the gold standard for the virological diagnosis of neurological severe infections (3), to date, no commercial fully automated PCR assay detecting both HSV and VZV is available. However, an FDA-approved assay for HSV detection in cerebrospinal fluid (CSF) was recently validated for clinical use (13,14). As low viral loads (Ͻ500 copies/ml) are not infrequent in CSF of patients suffering encephalitis associated with , it was recommended to reach a sensitivity of at least 200 copies/ml for the detection of this agent in CSF (21). The same need for sensitive tests is found with encephalitis associated with VZV (15, 22). The recently commercialized BD Max system (Becton Dickinson, Pont-de-Claix, France) combines the extraction and amplification steps on the same instrument, shortening the hands-on time and allowing its use in emergency molecular diagnostic testing. Dedicated analyte kits (23-26) but also master mix from other companies (27) and laboratory-developed methods (28) can be